FY2025 Earnings Estimate for AURA Issued By Leerink Partnrs

Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Equities research analysts at Leerink Partnrs reduced their FY2025 earnings per share (EPS) estimates for Aura Biosciences in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($1.98) per share for the year, down from their previous forecast of ($1.93). The consensus estimate for Aura Biosciences' current full-year earnings is ($1.66) per share. Leerink Partnrs also issued estimates for Aura Biosciences' FY2026 earnings at ($2.27) EPS.

Several other research analysts have also issued reports on AURA. Lifesci Capital upgraded shares of Aura Biosciences to a "strong-buy" rating in a report on Friday, January 31st. Scotiabank boosted their target price on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a "sector outperform" rating in a report on Friday, October 18th. BTIG Research increased their price target on Aura Biosciences from $21.00 to $24.00 and gave the stock a "buy" rating in a report on Friday, October 18th. Cowen reissued a "buy" rating on shares of Aura Biosciences in a research note on Friday, October 18th. Finally, HC Wainwright restated a "buy" rating and set a $22.00 target price on shares of Aura Biosciences in a research report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $23.00.

Aura Biosciences Price Performance

Shares of Aura Biosciences stock traded up $0.02 during trading on Monday, hitting $7.94. The company's stock had a trading volume of 104,036 shares, compared to its average volume of 130,553. The stock has a market cap of $396.61 million, a price-to-earnings ratio of -4.59 and a beta of 0.29. Aura Biosciences has a 52 week low of $6.63 and a 52 week high of $12.38. The stock has a 50-day moving average price of $8.11 and a two-hundred day moving average price of $8.81.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02.

Institutional Investors Weigh In On Aura Biosciences

Several institutional investors have recently bought and sold shares of AURA. The Manufacturers Life Insurance Company grew its stake in shares of Aura Biosciences by 14.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company's stock worth $487,000 after acquiring an additional 8,194 shares in the last quarter. SG Americas Securities LLC purchased a new position in Aura Biosciences during the third quarter worth about $169,000. Charles Schwab Investment Management Inc. grew its position in Aura Biosciences by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company's stock worth $1,233,000 after purchasing an additional 3,612 shares in the last quarter. State Street Corp increased its stake in Aura Biosciences by 3.7% in the 3rd quarter. State Street Corp now owns 754,803 shares of the company's stock valued at $6,725,000 after buying an additional 26,841 shares during the last quarter. Finally, Wellington Management Group LLP bought a new position in shares of Aura Biosciences during the 3rd quarter worth approximately $1,037,000. Institutional investors own 96.75% of the company's stock.

Insider Activity at Aura Biosciences

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares in the company, valued at approximately $2,336,987.64. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Janet Jill Hopkins sold 11,822 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.36, for a total value of $110,653.92. Following the completion of the sale, the insider now directly owns 151,693 shares of the company's stock, valued at approximately $1,419,846.48. This trade represents a 7.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,778 shares of company stock valued at $240,706 in the last three months. Corporate insiders own 5.40% of the company's stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.